Description
AOD-9604 + CJC-1295 + Ipamorelin 12 mg | Pure Lab Peptides Supply
Buy AOD-9604 + CJC-1295 + Ipamorelin 12 mg from Pure Lab Peptides Supply, supplied as lyophilized powder in one vial containing 12 mg of total labeled research material. This multi-peptide formulation combines three distinct synthetic peptides: AOD-9604, CJC-1295, and Ipamorelin.
Each component has a different amino acid structure and molecular classification. Specifically, AOD-9604 represents a modified growth hormone fragment, CJC-1295 belongs to the GHRH analogue category, and Ipamorelin is a synthetic pentapeptide. Together, these compounds form a three-component research blend rather than one chemically defined molecule.
Product Overview
The three components have distinct molecular characteristics and research classifications.
AOD-9604 is a modified 16-amino-acid peptide derived from a region of human growth hormone. Its structure includes an N-terminal tyrosine and two cysteine residues that form a disulfide bond.
CJC-1295 is a synthetic 29-amino-acid analogue of growth hormone-releasing hormone. However, its exact molecular structure depends on the supplied form. CJC-1295 with DAC contains an additional drug-affinity complex modification, whereas the No DAC form does not.
Ipamorelin is a synthetic pentapeptide containing five amino acid residues. Its modified amino acid structure distinguishes it from other compounds in the growth hormone secretagogue research category.
Furthermore, the combination brings these three separate molecular identities into one vial. Therefore, researchers should evaluate each component independently when reviewing product specifications and analytical documentation.
Product Information
| Specification | Details |
|---|---|
| Product name | AOD-9604 + CJC-1295 + Ipamorelin |
| Labeled quantity | 12 mg total |
| Presentation | One vial |
| Physical format | Lyophilized powder |
| Compound class | Three-component synthetic peptide blend |
| Components | AOD-9604, CJC-1295, Ipamorelin |
| Component sequence lengths | 16, 29, and 5 amino acids, respectively |
| CJC-1295 form | Confirm DAC or No DAC from product documentation |
| Product type | Research material |
| Intended application | Laboratory research and analytical reference |
| Documentation | Certificate of Analysis (COA) |
Molecular Characteristics
Each component has its own molecular formula, molecular weight, and chemical identity. Consequently, the complete blend does not have one universal molecular formula or molecular weight.
The following table presents reference characteristics for the individual peptides. For CJC-1295, the exact specifications depend on whether the product contains the DAC or No DAC form.
| Component | Reference Characteristics |
|---|---|
| AOD-9604 | Modified 16-amino-acid peptide |
| AOD-9604 CAS No. | 221231-10-3 |
| AOD-9604 molecular formula | C78H123N23O23S2 |
| AOD-9604 molecular weight | Approximately 1,815.1 g/mol |
| CJC-1295 | Modified 29-amino-acid GHRH analogue |
| CJC-1295 CAS No. | Form-dependent; confirm product specification |
| CJC-1295 molecular formula | Form-dependent |
| CJC-1295 molecular weight | Form-dependent |
| Ipamorelin | Modified synthetic pentapeptide |
| Ipamorelin CAS No. | 170851-70-4 |
| Ipamorelin molecular formula | C38H49N9O5 |
| Ipamorelin molecular weight | Approximately 711.9 g/mol |
| Complete blend formula | Not applicable; multi-component mixture |
| Complete blend molecular weight | Not applicable; multi-component mixture |
Understanding the Three-Peptide Combination
Although the three peptides share one product presentation, each retains its own molecular identity. Understanding these differences helps researchers evaluate the blend accurately.
AOD-9604
AOD-9604 is a modified peptide associated with the C-terminal region of human growth hormone. Its commonly referenced 16-residue sequence is:
YLRIVQCRSVEGSCGF
Additionally, the two cysteine residues form an intramolecular disulfide bond. This structural feature helps distinguish AOD-9604 from other growth hormone-related peptide materials.
CJC-1295
CJC-1295 is a modified 29-residue peptide analogue of growth hormone-releasing hormone. Its structure includes modifications that distinguish it from the naturally occurring hormone.
Importantly, researchers must distinguish between the DAC and No DAC forms. The DAC version contains an additional drug-affinity complex modification. By comparison, the No DAC version lacks that modification.
Therefore, the exact CJC-1295 form matters when documenting molecular characteristics. Researchers should confirm the supplied variant before assigning a molecular formula, molecular weight, or complete chemical sequence.
Ipamorelin
Ipamorelin is a synthetic pentapeptide with a commonly referenced sequence:
Aib-His-D-2-Nal-D-Phe-Lys-NH2
Its structure contains five amino acid residues, including modified amino acid components and a C-terminal amide. Consequently, its molecular characteristics differ from those of AOD-9604 and CJC-1295.
Why Choose the 12 mg Presentation?
The 12 mg presentation provides a clearly labeled total quantity of research material in one lyophilized vial.
Moreover, the combination brings together three distinct peptide identities in one product presentation. This makes accurate component identification and batch documentation particularly important.
Key product characteristics include:
- Three-component formulation: Combines AOD-9604, CJC-1295, and Ipamorelin.
- Distinct molecular identities: Each component has its own sequence and chemical characteristics.
- Total labeled quantity: 12 mg per vial.
- Lyophilized presentation: Provides the material in dry powder form.
- Documentation access: Available COA information supports product and batch review.
Importantly, the 12 mg label refers to the total stated dry material mass. It does not mean that each peptide contributes 12 mg. Similarly, the label does not establish the individual component quantities or a prepared solution concentration.
Quality Documentation and COA
Accurate documentation plays an important role in evaluating multi-peptide formulations. Since each component has a separate molecular structure, researchers should review the available batch information carefully.
Pure Lab Peptides Supply provides access to its Certificate of Analysis (COA) page.
When reviewing the applicable documentation, consider these details:
- Confirmation of all three peptide identities.
- Identification of the specific CJC-1295 form.
- Individual component quantities or blend ratios, where reported.
- Analytical methods used for component identification.
- Reported purity and other available batch results.
Furthermore, one overall purity figure does not necessarily establish the identity or quantity of every component. For this reason, component-specific analytical information provides useful additional context.
Discreet Delivery with Pure Lab Peptides Supply
Pure Lab Peptides Supply prioritizes discreet and secure order handling. Eligible shipments use odor-proof, tamper-resistant, non-branded packaging to help protect package privacy during transit.
Additionally, tracking information allows customers to follow shipment progress. This approach supports a professional delivery experience while keeping external packaging simple and discreet.
Storage and Handling
Follow the product label and applicable documentation when storing lyophilized research materials. In addition, protect the vial from unnecessary exposure to moisture, heat, and direct light.
Use appropriate laboratory handling procedures and consult the relevant product records before conducting analytical work. However, do not assume a specific storage temperature, reconstitution method, or post-reconstitution stability period without supporting product information.
Frequently Asked Questions
What peptides are included in this 12 mg blend?
The product name identifies three components: AOD-9604, CJC-1295, and Ipamorelin. However, the individual quantities require confirmation through the applicable product specifications.
Does the 12 mg label mean 12 mg of each peptide?
No. The 12 mg label represents the total stated quantity of the blend. It does not establish the amount of each individual component.
Is CJC-1295 DAC the same as CJC-1295 No DAC?
No. These forms have different molecular structures. Specifically, the DAC form contains an additional drug-affinity complex modification that the No DAC form lacks.
Does the complete blend have one molecular formula?
No. Each peptide has its own molecular formula. Because the product combines three components, the complete blend does not have one universal molecular formula or molecular weight.
Is the product supplied as a liquid?
No. The stated presentation is lyophilized powder in one vial.
Where can I find product documentation?
Visit the Pure Lab Peptides Supply COA page to access available documentation. For accurate product identification, consult the applicable batch record.
Order AOD-9604 + CJC-1295 + Ipamorelin 12 mg
Explore the AOD-9604 + CJC-1295 + Ipamorelin 12 mg combination from Pure Lab Peptides Supply for laboratory research and analytical reference applications.
Each vial contains a labeled total quantity of 12 mg in lyophilized powder form. Furthermore, the product information distinguishes all three components to support accurate material identification and research documentation.
Review the applicable product specifications and COA information to confirm the individual component identities, quantities, and CJC-1295 form.

















